Media & InvestorBusiness strategy
BioTransformations has developed a platform technology with the potential for many valuable applications and is now seeking funding to demonstrate proof of principle for one application with the anticipation that this will attract interest from major pharmaceutical companies leading to licensing agreements or sale of the company at a significant valuation.
Where appropriate, the Company will adopt a risk-sharing approach by out-licensing its technology to commercial development partners. Depending on the stage of development for a particular technology, a commercial development partner would either:
- license the technology directly for immediate commercial exploitation and marketing;
- or fund the final stages of technology development in preparation for its market offering and eventual sale.
In exchange, BioTransformations would envisage negotiating up-front and milestone payments through to entry of the product onto the market, and royalties on future sales.
BioTransformations is strongly positioned to achieve its business strategy and the following attributes provide the foundations for its success:
- Innovative enabling platform technology.
- Experienced management and technical teams, focused on realising the commercial potential of the Company’s technologies.
- Appropriate patent coverage.
- A conservative development plan with realistic and achievable goals.